The present invention provides a diagnostic agent for lung cancer, as well as pharmaceutical compositions for the treatment of lung cancer. Specifically, a diagnostic agent for lung cancer and pharmaceutical compositions for containing an antibody capable of binding to -20 receptor β chain interleukin...
Further studies with these new drugs utilized in combination chemo therapeutic regimens are needed to define the role of these agents in the treatment of patients with SCLC.doi:10.1016/S0169-5002(10)80018-2DavidS.EttingerLung CancerEttinger DS. New drugs for treating small cell lung cancer. ...
Non-small cell lung cancerChemotherapyPhase II drugsDavid S. EttingerLung CancerEttinger DS. New drugs in the treatment of non-small cell lung cancer. Lung Cancer 1991; 7: 113-22.Ettinger DS. New drugs in the treatment of non-small cell lung cancer. Lung Cancer 1991;7: 113–122....
Introduction: Despite the high response rate to chemotherapy, there have been few advances in the treatment of small-cell lung cancer (SCLC) in the last decades. The state-of-the-art second-line therapy and future research developments in relapsed SCLC are reviewed.Areas covered: There are no...
There are so many drugs on the market for lung cancer treatment. By and large they are becoming more targeted for purpose, with less destruction of healthy tissue The main types used to treat lung cancer are: Carboplatin: is a long standing drug. It is a colourless liquid, usually given ...
major health burden around the world. This timely reference surveys and evaluates the drug treatments available for the main categories of lung diseases including asthma, tuberculosis, chronic obstructive pulmonary disease, lung cancer, and respiratory infections. The recent re-emergence of tuberculosis ...
p110α are currently showing promise inclinical trialsagainst certain breast cancers, so could be approved for clinical use in the near future. The new findings suggest that these drugs could potentially benefit patients with EGFR-mutant lung cancers whose tumours have become resistant totreatment. ...
This cross-sectional study examines trends in costs of brand-name medications for treatment of non–small cell lung cancer and within-class price
The use of chemotherapy is considered standard therapy in patients with locally advanced non-small-cell lung cancer that cannot be treated with radiotherapy and in those with metastatic non-small-cell lung cancer and good performance status. This approac
Lord, a Cancer Research-UK funded scientist at The Institute of Cancer Research (ICR), said: "This study suggests that PARP inhibitors – treatments already in clinical trials to treat breast andovarian cancer– could also be a promising treatment for patients with certain forms of lung cancer....